BillionToOne, Inc. (BLLN)
NASDAQ: BLLN · Real-Time Price · USD
72.11
-1.40 (-1.90%)
At close: Mar 9, 2026, 4:00 PM EDT
72.40
+0.29 (0.40%)
After-hours: Mar 9, 2026, 7:59 PM EDT

Company Description

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics.

The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection.

It offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a test that provides longitudinal determination of cancer burden through methylation assessment.

The company was incorporated in 2016 and is headquartered in Menlo Park, California.

BillionToOne, Inc.
BillionToOne logo
Country United States
Founded 2016
IPO Date Nov 6, 2025
Industry Diagnostics & Research
Sector Healthcare
Employees 620
CEO Oguzhan Atay

Contact Details

Address:
1035 O’Brien Drive
Menlo Park, California 94025
United States
Phone (650) 460-2551
Website billiontoone.com

Stock Details

Ticker Symbol BLLN
Exchange NASDAQ
Stock Type Common Stock
Share Class Class A Shares
Fiscal Year January - December
Reporting Currency USD
IPO Price $60.00
CIK Code 0002070849
CUSIP Number 090168105
ISIN Number US0901681058
Employer ID 81-1082020
SIC Code 8071

Key Executives

Name Position
Dr. Oguzhan Atay Ph.D. Co-Founder, Chairman and Chief Executive Officer
Dr. David Tsao Ph.D. Co-Founder, President, Chief Technology Officer and Director
Ross Taylor Jr., M.B.A. Chief Financial Officer
Nancy Johnson Senior Vice President of Sales and Commercial Operations
Jean Hayden Vice President of Business Operations and Chief of Staff
John D. Lister J.D. Chief Administrative Officer
Thomas P. Lynch J.D. Chief Compliance Officer, General Counsel and Secretary
Jaclyn Eng Vice President of Marketing
Vaghar Haghiri Senior Director of People Operations
Shan Riku Sakakibara M.B.A. Chief Product Officer

Latest SEC Filings

Date Type Title
Mar 4, 2026 8-K Current Report
Feb 17, 2026 SCHEDULE 13G Filing
Feb 17, 2026 SCHEDULE 13G Filing
Feb 13, 2026 SCHEDULE 13G Filing
Jan 20, 2026 SCHEDULE 13D Filing
Jan 12, 2026 8-K Current Report
Dec 10, 2025 10-Q Quarterly Report
Dec 9, 2025 8-K Current Report
Nov 10, 2025 8-K Current Report
Nov 6, 2025 424B4 Prospectus